Skip to main navigation Skip to search Skip to main content

Copy-number variation of the glucose transporter gene SLC2A3 and congenital heart defects in the 22q11.2 deletion syndrome

  • Elisabeth E. Mlynarski
  • , Molly B. Sheridan
  • , Michael Xie
  • , Tingwei Guo
  • , Silvia E. Racedo
  • , Donna M. McDonald-Mcginn
  • , Xiaowu Gai
  • , Eva W.C. Chow
  • , Jacob Vorstman
  • , Ann Swillen
  • , Koen Devriendt
  • , Jeroen Breckpot
  • , Maria Cristina Digilio
  • , Bruno Marino
  • , Bruno Dallapiccola
  • , Nicole Philip
  • , Tony J. Simon
  • , Amy E. Roberts
  • , Małgorzata Piotrowicz
  • , Carrie E. Bearden
  • Stephan Eliez, Doron Gothelf, Karlene Coleman, Wendy R. Kates, Marcella Devoto, Elaine Zackai, Damian Heine-Suñer, Tamim H. Shaikh, Anne S. Bassett, Elizabeth Goldmuntz, Bernice E. Morrow, Beverly S. Emanuel*
*Corresponding author for this work
  • The Children's Hospital of Philadelphia
  • Albert Einstein College of Medicine
  • University of Pennsylvania
  • Harvard University
  • University of Toronto
  • Utrecht University
  • KU Leuven
  • IRCCS Ospedale pediatrico Bambino Gesù - Roma
  • University of Rome La Sapienza
  • Aix-Marseille Université
  • University of California at Davis
  • Boston Children's Hospital
  • Institute of Polish Mother's Health Center
  • University of California at Los Angeles
  • University of Geneva
  • Emory University
  • SUNY Upstate Medical University
  • Hospital Universitario Son Espases
  • University of Colorado Anschutz Medical Campus

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

The 22q11.2 deletion syndrome (22q11DS; velocardiofacial/DiGeorge syndrome; VCFS/DGS) is the most common microdeletion syndrome and the phenotypic presentation is highly variable. Approximately 65% of individuals with 22q11DS have a congenital heart defect (CHD), mostly of the conotruncal type, and/or an aortic arch defect. The etiology of this phenotypic variability is not currently known. We hypothesized that copy-number variants (CNVs) outside the 22q11.2 deleted region might increase the risk of being born with a CHD in this sensitized population. Genotyping with Affymetrix SNP Array 6.0 was performed on two groups of subjects with 22q11DS separated by time of ascertainment and processing. CNV analysis was completed on a total of 949 subjects (cohort 1, n = 562; cohort 2, n = 387), 603 with CHDs (cohort 1, n = 363; cohort 2, n = 240) and 346 with normal cardiac anatomy (cohort 1, n = 199; cohort 2, n = 147). Our analysis revealed that a duplication of SLC2A3 was the most frequent CNV identified in the first cohort. It was present in 18 subjects with CHDs and 1 subject without (p = 3.12 × 10-3, two-tailed Fisher's exact test). In the second cohort, the SLC2A3 duplication was also significantly enriched in subjects with CHDs (p = 3.30 × 10-2, two-tailed Fisher's exact test). The SLC2A3 duplication was the most frequent CNV detected and the only significant finding in our combined analysis (p = 2.68 × 10-4, two-tailed Fisher's exact test), indicating that the SLC2A3 duplication might serve as a genetic modifier of CHDs and/or aortic arch anomalies in individuals with 22q11DS.

Original languageEnglish
Pages (from-to)753-764
Number of pages12
JournalAmerican Journal of Human Genetics
Volume96
Issue number5
DOIs
StatePublished - 7 May 2015

Funding

FundersFunder number
NIH/NCATS
National Institutes of HealthHD070454, MH87636, HL84410
National Institute of Child Health and Human DevelopmentP30HD026979
National Center for Advancing Translational SciencesUL1TR000003

    Fingerprint

    Dive into the research topics of 'Copy-number variation of the glucose transporter gene SLC2A3 and congenital heart defects in the 22q11.2 deletion syndrome'. Together they form a unique fingerprint.

    Cite this